ribavirin, 36791-04-5

Articles:

PubMed:	Hepatitis C virus: Virology, diagnosis and treatment.
PubMed:	Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens.
PubMed:	Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs.
PubMed:	Faldaprevir for the treatment of hepatitis C.
PubMed:	Preparation of monoPEGylated Cyanovirin-N's derivative and its anti-influenza A virus bioactivity in vitro and in vivo.
PubMed:	Ribavirin stimulates the immune response of Atlantic salmon.
PubMed:	Application of "hydrogen bonding interaction" in new drug development: design, synthesis, antiviral activity, and SARs of thiourea derivatives.
PubMed:	Development of live-attenuated arenavirus vaccines based on codon deoptimization.
PubMed:	FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin.
PubMed:	Anti-Mayaro virus activity of Cassia australis extracts (Fabaceae, Leguminosae).
PubMed:	[A hantavirus killed an Israeli researcher: hazards while working with wild animals].
PubMed:	Design, synthesis, and antiviral, fungicidal, and insecticidal activities of tetrahydro-β-carboline-3-carbohydrazide derivatives.
PubMed:	D and E rings may not be indispensable for antofine: discovery of phenanthrene and alkylamine chain containing antofine derivatives as novel antiviral agents against tobacco mosaic virus (TMV) based on interaction of antofine and TMV RNA.
PubMed:	Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.
PubMed:	Treatment of hepatitis C: a systematic review.
PubMed:	Antiviral medications for the treatment of hepatitis B and C infection and their effects on kidney function.
PubMed:	Sofosbuvir for the treatment of chronic hepatitis C virus infection.
PubMed:	Emerging therapeutic options for the management of hepatitis C infection.
PubMed:	Hepatitis C in HIV-infected patients: impact of direct-acting antivirals.
PubMed:	Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection.
PubMed:	Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.
PubMed:	Synthesis and antiviral and fungicidal activity evaluation of β-carboline, dihydro-β-carboline, tetrahydro-β-carboline alkaloids, and their derivatives.
PubMed:	[Epidemiology of hepatitis E virus infection in Spain].
PubMed:	Antiviral treatment of hepatitis C virus infection and factors affecting efficacy.
PubMed:	Antiviral activity of polymethoxylated flavones from "Guangchenpi", the edible and medicinal pericarps of citrus reticulata 'Chachi'.
PubMed:	Sofosbuvir approved for chronic hepatitis C infection.
PubMed:	New rubrolides from the marine-derived fungus Aspergillus terreus OUCMDZ-1925.
PubMed:	Sofosbuvir for the treatment of hepatitis C virus.
PubMed:	Hepatitis E infection in liver transplant recipients.
PubMed:	Hepatitis E: the forgotten virus.
PubMed:	Optimizing DAA management in daily practice.
PubMed:	The pharmacokinetic evaluation of boceprevir for treatment of hepatitis C virus.
PubMed:	[Biochemical and pharmacological features of telaprevir].
PubMed:	Jiawei-Yupingfeng-Tang, a Chinese herbal formula, inhibits respiratory viral infections in vitro and in vivo.
PubMed:	Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1.
PubMed:	Evolution of cell culture systems for HCV.
PubMed:	In vivo inhibition of trans-plasma membrane electron transport by antiviral drugs in grapevine.
PubMed:	A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
PubMed:	Anti-human rhinovirus 2 activity and mode of action of quercetin-7-glucoside from Lagerstroemia speciosa.
PubMed:	Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions.
PubMed:	Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies.
PubMed:	Arenavirus reverse genetics for vaccine development.
PubMed:	Boceprevir in chronic hepatitis C infection: a perspective review.
PubMed:	Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection.
PubMed:	Establishment of SYBR green-based qPCR assay for rapid evaluation and quantification for anti-Hantaan virus compounds in vitro and in suckling mice.
PubMed:	Enhanced inhibition of foot-and-mouth disease virus by combinations of porcine interferon-α and antiviral agents.
PubMed:	Boceprevir: a protease inhibitor for the treatment of hepatitis C.
PubMed:	Telaprevir: pharmacokinetics and drug interactions.
PubMed:	Telaprevir: a hepatitis C NS3/4A protease inhibitor.
PubMed:	Hepatitis in the elderly: still a scourge.
PubMed:	Design, synthesis, and antiviral activity evaluation of phenanthrene-based antofine derivatives.
PubMed:	Telaprevir and boceprevir in African Americans with genotype 1 chronic hepatitis C: implications for patients and providers.
PubMed:	New pharmacotherapy for hepatitis C.
PubMed:	Therapeutic vaccination against chronic hepatitis C virus infection.
PubMed:	Ribavirin, a nucleoside with potential insecticidal activity.
PubMed:	Interferon responsiveness does not change in treatment-experienced hepatitis C subjects: implications for drug development and clinical decisions.
PubMed:	Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.
PubMed:	Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-naïve and -experienced subjects.
PubMed:	New genetic discoveries and treatment for hepatitis C.
PubMed:	Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naïve and experienced subjects.
PubMed:	Advances in the treatment of hepatitis C virus infection.
PubMed:	Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.
PubMed:	[Hepatitis E: molecular virology, epidemiology and pathogenesis].
PubMed:	A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.
PubMed:	The Role of IL28B Genotype Testing in the Era of Direct Acting Antiviral Agents.
PubMed:	The era of direct-acting antivirals has begun: the beginning of the end for HCV?
PubMed:	Telaprevir: an oral protease inhibitor for hepatitis C virus infection.
PubMed:	Quantitative trace analysis of a broad range of antiviral drugs in poultry muscle using column-switch liquid chromatography coupled to tandem mass spectrometry.
PubMed:	Recent advance in antiviral drugs for hepatitis C.
PubMed:	FDA notifications. Renal impairment addressed in labeling.
PubMed:	Management of chronic hepatitis C infection in children.
PubMed:	Telaprevir: looking for a sustained virologic response in hepatitis C virus infection.
PubMed:	In vitro activity of Paris polyphylla smith against enterovirus 71 and coxsackievirus B3 and its immune modulation.
PubMed:	Boceprevir.
PubMed:	Interferon-lambda and therapy for chronic hepatitis C virus infection.
PubMed:	Wheezing in infancy.
PubMed:	Bronchiolitis.
PubMed:	Hepatitis C pharmacogenetics: state of the art in 2010.
PubMed:	Current therapies for chronic hepatitis C.
PubMed:	High-content assay to identify inhibitors of dengue virus infection.
PubMed:	5-Methyl-1,2,3-thiadiazoles synthesized via ugi reaction and their fungicidal and antiviral activities.
PubMed:	Anti-human rhinovirus activity of raoulic acid from Raoulia australis.
PubMed:	Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System.
PubMed:	Chronic hepatitis C virus infection in children and adolescents: Epidemiology, natural history, and assessment of the safety and efficacy of combination therapy.
PubMed:	Taste disturbances during therapy with pegylated interferon-alpha 2b and ribavirin in patients with chronic hepatitis C.
PubMed:	[Effects of Tankejing dry powder inhaler on the inflammatory damage in the lungs of mice infected by FM1].
PubMed:	[Anti-viral effects of Tankejing preparations against influenza virus A].
PubMed:	Evidence-based antimicrobial therapy in pregnancy: long overdue.
PubMed:	Original research: Intravenous ribavirin--review of the FDA's Emergency Investigational New Drug Database (1997-2008) and literature review.
PubMed:	Effect of dietary purines on the pharmacokinetics of orally administered ribavirin.
PubMed:	Acrolein, a ubiquitous pollutant and lipid hydroperoxide product, inhibits antiviral activity of interferon-alpha: relevance to hepatitis C.
PubMed:	Treatment for chronic hepatitis C in children: a review.
PubMed:	Severe hepatocellular injury with apoptosis induced by a hepatitis C polymerase inhibitor.
PubMed:	Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay.
PubMed:	Hepatitis C: current and future therapies.
PubMed:	The impact of combination therapy with peginterferon alpha-2a and ribavirin on the energy intake and body weight of adult hepatitis C patients.
PubMed:	Overcoming hurdles in hepatitis C virus research: efficient production of infectious virus in cell culture.
PubMed:	Oral lesions in HIV and HCV co-infected individuals in HAART era.
PubMed:	Stability-indicating thin-layer chromatographic method for quantitative determination of ribavirin.
PubMed:	Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection.
PubMed:	Gastrointestinal medications in pregnancy.
PubMed:	Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy.
PubMed:	Bronchiolitis.
PubMed:	Hepatitis C (chronic).
PubMed:	Development of a tomato-based food for special medical purposes as therapy adjuvant for patients with HCV infection.
PubMed:	Pharmacokinetics of ribavirin in patients with hepatitis C virus.
PubMed:	Bupleurum kaoi inhibits Coxsackie B virus type 1 infection of CCFS-1 cells by induction of type I interferons expression.
PubMed:	[Inhibitory effect of new antimicrobial substance by Bacillus subtilis fmbJ on Newcastle disease virus and infectious Bursal disease virus in vitro].
PubMed:	FDA approves Pegasys and Copegus for hepatitis C in patients with HIV co-infection.
PubMed:	Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.
PubMed:	Clinical experience with nonstandard doses ofinterferon alfa-2b and ribavirin in the treatment of chronic hepatitis C infection: A retrospective analysis.
PubMed:	Hepatitis drug gets approval for coinfection treatment.
PubMed:	The effect of zinc supplementation on the treatment of chronic hepatitis C patients with interferon and ribavirin.
PubMed:	Oxidative stress in chronic hepatitis C: a preliminary study on the protective effects of antioxidant flavonoids.
PubMed:	Maintenance therapy for chronic hepatitis C.
PubMed:	Crimean-Congo hemorrhagic fever.
PubMed:	Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.
PubMed:	Oxidative status in chronic hepatitis C: the influence of antiviral therapy and prognostic value of serum hydroperoxide assay.
PubMed:	Treatment Options for Hepatitis C Infection in Children.
PubMed:	Peginterferon alfa-2a: a review of approved and investigational uses.
PubMed:	FDA approves Hep C drugs.
PubMed:	Tomato-based functional food as interferon adjuvant in HCV eradication therapy.
PubMed:	Anti-HCV activities of selective polyunsaturated fatty acids.
PubMed:	Nucleoside analogues and mitochondrial toxicity.
PubMed:	Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
PubMed:	Hantavirus infection in children.
PubMed:	Pediatric drug labeling: improving the safety and efficacy of pediatric therapies.
PubMed:	Pediatric issues in new therapies for hepatitis B and C.
PubMed:	Hepatitis C: FDA public meeting on peginterferon plus ribavirin, Nov. 14.
PubMed:	Hepatitis C virus infection.
PubMed:	Ribavirin and chronic hepatitis C infection.
PubMed:	Ribavirin for hepatitis C: 80% price reduction available July 9?
PubMed:	Ribavirin approved with a big fat price.
PubMed:	Hepatitis C: new treatment overview.
PubMed:	Treating hepatitis C: a clinician's perspective. Interview by Bob Roehr.
PubMed:	Can science meet the challenges of the HCV pandemic: new treatment options for chronic hepatitis C.
PubMed:	Ribavirin approved for hepatitis C combination treatment.
PubMed:	FDA approves new combination treatment for hepatitis C. Food and Drug Administration.
PubMed:	Hepatitis C and HIV: ribavirin plus interferon study recruiting.
PubMed:	Hepatitis C important treatment advance: interview with Douglas Dieterich, M.D. Interview by John S. James.
PubMed:	Pediatric drug trials: women and children last?
PubMed:	The clinical pharmacology of ribavirin.
PubMed:	Underused options for preventing and treating influenza.
PubMed:	Hepatitis C not incurable.
PubMed:	From the Food and Drug Administration.
PubMed:	Evaluation of a rapid diagnostic test for respiratory syncytial virus (RSV): potential for bedside diagnosis.
PubMed:	Molecular mechanisms of action of ribavirin.
PubMed:	AIDS drug gets green light.
PubMed:	Ribavirin aerosol approved for severe cases of RSV in infants and young children.